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Background. Periprosthetic joint infection (PJI) is a devastating complication of joint replacement surgery. Most observational 
studies of PJI are retrospective or single-center, and reported management approaches and outcomes vary widely. We hypothesized 
that there would be substantial heterogeneity in PJI management and that most PJIs would present as late acute infections occurring 
as a consequence of bloodstream infections.
Methods. The Prosthetic joint Infection in Australia and New Zealand, Observational (PIANO) study is a prospective 
study at 27 hospitals. From July 2014 through December 2017, we enrolled all adults with a newly diagnosed PJI of a large 
joint. We collected data on demographics, microbiology, and surgical and antibiotic management over the first 3  months 
postpresentation.
Results. We enrolled 783 patients (427 knee, 323 hip, 25 shoulder, 6 elbow, and 2 ankle). The mode of presentation was late 
acute (>30 days postimplantation and <7 days of symptoms; 351, 45%), followed by early (≤30 days postimplantation; 196, 25%) and 
chronic (>30 days postimplantation with ≥30 days of symptoms; 148, 19%). Debridement, antibiotics, irrigation, and implant reten-
tion constituted the commonest initial management approach (565, 72%), but debridement was moderate or less in 142 (25%) and 
the polyethylene liner was not exchanged in 104 (23%).
Conclusions. In contrast to most studies, late acute infection was the most common mode of presentation, likely reflecting he-
matogenous seeding. Management was heterogeneous, reflecting the poor evidence base and the need for randomized controlled 
trials.
Keywords.  arthroplasty infection; artificial joint infection; periprosthetic jo int infection.
Periprosthetic joint infection (PJI) is a devastating complica-
tion of joint arthroplasty, resulting in pain, suffering, impaired 
mobility, prolonged hospitalization, broad-spectrum antibiotic 
therapy, and societal and economic costs [1–3].
Although arthroplasty revision operations performed for 
infection have progressively increased [4], estimates from 
arthroplasty registry data or infection control surveillance may 
underestimate the true incidence of PJI [5, 6]. Unlike early post-
operative or chronic low-grade infections, these data sources do 
not reliably capture late acute PJI (LA-PJI), which may not be 
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managed with revision arthroplasty, or may present after sur-
veillance activities are complete and might account for these 
underestimates. Treatment success rates for PJI vary widely [7] 
and are likely to be dependent on a number of patient, micro-
biological, and treatment factors. There are few randomized 
controlled trials to guide management, and most studies are 
retrospective [8, 9]. Reported prospective studies are small or 
reported from single centers with specialized PJI expertise. To 
date, no multicenter prospective observational study has been 
sufficiently large to describe contemporary clinical characteris-
tics, etiology, and management across diverse regions and clin-
ical settings, or to link treatment outcomes in terms of initial 
management, surgical methods, or antibiotic therapy.
To fill this knowledge gap, we established the Prosthetic joint 
Infection in Australia and New Zealand (NZ), Observational 
(PIANO) study. We hypothesized that across different hospital 
settings from the private and public sectors, late acute PJI would 
comprise a larger proportion of the PJI burden than had been 
reported previously and that there would be heterogeneity in in-
itial management approaches that deviated from international 
guidelines [10, 11]. Here we report the baseline and initial fol-
low-up data to 90 days after diagnosis. Extended follow-up and 
2-year outcome data are still being collected.
METHODS
Study Sites and Ethical Approval
The PIANO study is a prospective, binational, multicenter ob-
servational cohort study conducted at 27 hospitals in Australia 
and New Zealand, identified through the Australasian Society 
for Infectious Diseases Clinical Research Network. Ethical ap-
provals were obtained from each site, and the study was reg-
istered (ANZCTR12615001357549). All participants provided 
written informed consent.
Participants
Participants were prospectively identified and enrolled after 
referral from orthopedic and infectious diseases/microbiology 
teams at each institution. Adult patients (>18 years old) with a 
newly identified PJI of a large joint (hip, knee, shoulder, elbow, 
wrist, or ankle) were eligible when diagnosed according to the 
presence of at least 1 of the following: (i) presence of sinus tract 
in communication with the prosthesis; (ii) increased leukocyte 
count or neutrophil percentage in preoperative synovial fluid 
aspirate (synovial fluid white blood cell count >1700 cells/
μL or neutrophil percentage >65%); (iii) visible pus around 
the prosthesis at operation without alternative explanation; 
iv) acute inflammation as reported by the clinical pathologist 
on examination of periprosthetic tissue (≥5 neutrophils per 
high-power field); (v) ≥2 preoperative or intraoperative cul-
tures (blood, synovial fluid, periprosthetic tissue, or sonication 
fluid) that yielded the same organism (indistinguishable based 
on common laboratory tests including genus and species iden-
tification or common antibiogram); or (vi) pure growth of 
Staphylococcus aureus, β-hemolytic streptococci, or patho-
genic aerobic gram-negative rod from a single synovial fluid or 
intraoperative tissue/fluid specimen. These diagnostic criteria 
for PJI reflected international guidelines at the time the study 
was designed.
Patients were excluded if they were not likely to be accessible 
by telephone for follow-up or presented with complications 
from a PJI diagnosed before the study period. All laboratories 
used traditional culture-based methods on blood cultures, syn-
ovial fluid, periprosthetic joint tissue, or explanted prosthesis 
components.
Data Management and Statistical Analysis
Data were collected at baseline and 3 months and entered into 
a purpose-built web-based database. The statistical program R 
was used for statistical analyses [12]. Continuous data are pre-
sented as median and interquartile range (IQR), and compari-
sons between groups were by nonparametric tests. Comparisons 
between categorical variables were analyzed with a chi-square 
test.
Definitions
We defined early PJI as the date of diagnosis occurring 
≤30  days after the original arthroplasty operation. Late acute 
PJI (LA-PJI) was defined as occurring >30 days from implanta-
tion, but with a duration of symptoms ≤7 days and no evidence 
of a sinus overlying the joint. Patients with a late-onset infec-
tion (>30 days from implantation) and a prolonged duration of 
symptoms (>30 days) at the time of diagnosis or the presence 
of a sinus were considered to be late chronic PJI. Patients with 
late-onset PJI, a duration of symptoms between 8 and 30 days, 
and without the presence of a sinus were considered to have 
late indeterminate infections. The remainder were considered 
late unclassifiable PJI. If the exact date of arthroplasty implan-
tation was not available, it was estimated to be the first day of 
the nearest month or the year that the patient recalled having 
the operation.
We also categorized patients according to whether they 
were culture negative (no organisms isolated from microbio-
logical samples), monomicrobial (1 clinically significant or-
ganism isolated), or polymicrobial (>1 clinically significant 
organism). The initial surgical management was categorized as 
(i) debridement, antibiotics, irrigation, and implant retention 
(DAIR), (ii) 2-stage exchange arthroplasty, (iii) single-stage ex-
change arthroplasty, (iv) suppressive antibiotics alone, (v) ex-
cision arthroplasty, or (vi) no clear plan identified. The degree 
of operative debridement was classified as minor (lavage with 








niversity user on 30 July 2021
Prosthetic Joint Infection in Australia and New Zealand, Observational (PIANO) Study • ofid • 3
periprosthetic pus, infected tissue, and loose cement), or mod-
erate (more than minimal but less than extensive).
RESULTS
Baseline Characteristics
From July 2014 to December 31, 2017, 783 patients were en-
rolled into the PIANO study (Figure  1). The median (IQR, 
range) age and body mass index (BMI) were 69 years (62–77, 
28–99) and 31 kg/m2 (27–37, 16–57), respectively. Male gender 
(57.0%) and right-sided PJIs (55.7%) were more common. 
The most commonly affected joint was the knee (427, 54.5%), 
followed by hip (323, 41.3%), shoulder (25, 3.2%]), elbow (6, 
0.8%), and ankle (2, 0.3%). The most common comorbidities 
included diabetes mellitus (172, 22.1%) and ischemic heart 
disease (131, 16.8%) (Table  1). After adjustment for multiple 
comparisons, none of the comorbidities were associated with 
the type of PJI. Sixteen (2.1%) deaths occurred within the first 
90 days after diagnosis of PJI.
Classification of PJI, Based on Time From Implantation and Duration of 
Symptoms
Late acute PJI accounted for 351 (44.8%) episodes. Early PJI 
occurred in 196 patients (25.0%) and late chronic infections in 
148 (18.9%) patients. The remainder had late infections, with 
duration of symptoms between 8 and 30 days (55, 7.0%), or 
unspecified duration of symptoms (32, 4.1%) (Figure 2A and 
B, Table  1). When late indeterminate groups were excluded, 
LA-PJI accounted for nearly half of all classifiable PJI. The af-
fected joint according to prosthesis age is shown (Figure  2E 
and F). When comparing PJI in hips and knees, infections 
of knee prostheses accounted for a higher proportion of PJI 
1072 screened patients with suspected PJI
105 did not meet clinical inclusion criteria
184 were excluded due to:
Not competent to consent (56)
Refused consent (36)
Transferred or discharged before enrollment (19)
Inaccessible for follow-up (13)
Other infected hardware (8)
Enrolled in other PJI study (6)
Chronic infection diagnosed previously (5)
Clinician determined (5)
Died before consent (3)
Too sick (2)






- GAS(5), GBS (32), GCGS (43), other (6)
Coagulase-negative staphylococci (179)
- S. lugdenensis (23)
- S. capitis (20)































Figure 1. Flowchart of study and microbiological causes of periprosthetic infection. Abbreviations: GAS, Group A Streptococcus; GBS, Group B Streptococcus; GCGS, Group 
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Table 1. Clinical Characteristics, Laboratory Findings, and Initial Management Strategy of Patients With Periprosthetic Joint Infection According to 
Infection Type
Characteristic







8–30 d)  
(n = 55)
Late (Unspecified)  
(n = 32) P
Age, y 70 (62–78) 68 (61–76) 69 (62–77) 72 (68–76) 69 (55–77) .03
Gender
Male 217 (61.8) 108 (55.1) 72 (48.6) 33 (60.0) 19 (59.4) .09
Female 134 (38.2) 88 (44.9) 76 (51.4) 22 (40.0) 13 (40.6)  
Body mass index, kg/m2 31 (27–36) 33 (28–38) 31 (26–37) 31 (27–36) 29 (25–32) .03
Comorbidities (Y) (Y) (Y) (Y) (Y)  
Diabetes 92 (26.2) 35 (17.8) 26 (17.5) 12 (21.8) 7 (21.9) .13
Rheumatoid arthritis 31 (8.8) 8 (4.1) 10 (6.7) 7 (12.7) 3 (9.4) .15
Chronic renal impairment 33 (9.4) 8 (4.1) 15 (10.1) 5 (9.1) 2 (6.2) .19
End-stage renal failure 2 (0.5) 0 (0.0) 3 (2.0) 0 (0.0) 0 (0.0) .18
Cirrhosis 4 (1.1) 3 (1.5) 1 (0.7) 0 (0.0) 1 (3.1) .69
Malignancy 15 (4.2) 3 (1.5) 12 (8.1) 3 (5.4) 1 (3.1) .06
Congestive cardiac failure 27 (7.7) 7 (3.6) 5 (3.4) 6 (10.9) 1 (3.1) .07
Ischaemic heart disease 75 (21.3) 20 (10.2) 22 (14.8) 8 (14.5) 6 (18.7) .02
Corticosteroid use 29 (8.2) 17 (8.7) 13 (8.9) 6 (10.9) 1 (3.1) .77
Immunosuppressed 24 (6.8) 7 (3.6) 10 (6.7) 4 (7.3) 0 (0.0) .29
Active orders limiting life-sustaining 
treatment
3 (0.8) 1 (0.5) 3 (2.0) 0 (0.0) 0 (0.0) .52
Joint affected
Knee 244 (69.5) 72 (36.7) 69 (46.6) 26 (47.3) 12 (37.5)  
Hip 97 (27.6) 116 (59.2) 72 (48.6) 26 (47.3) 15 (46.9)  
Shoulder 8 (2.3) 5 (2.6) 4 (2.7) 3 (5.4) 5 (15.6) <.0001
Elbow 2 (0.6) 2 (1.0) 2 (1.4) 0 (0.0) 0 (0.0)  
Ankle 0 (0) 1 (0.5) 1 (0.7) 0 (0.0) 0 (0.0)  
Side
Right 189 (53.8) 118 (60.2) 75 (50.7) 33 (60.0) 20 (62.5) .32
Left 162 (46.2) 78 (39.8) 73 (49.3) 22 (40.0) 12 (37.5)  
Time from implant to diagnosis, d 952 (203–2814) 17 (12–22) 458 (104–1430) 434 (90–2334) 1434 (333–3176) <.0001
Indication for original implant
Primary 287 (81.8) 162 (82.7) 118 (79.7) 39 (70.9) 21 (65.6)  
Infection 20 (5.7) 3 (1.5) 6 (4.1) 3 (5.5) 3 (9.4) .02
Other/unknown 44 (12.5) 31 (15.8) 24 (16.2) 13 (23.6) 8 (25.0)  
Duration of symptoms, d 2 (1–5) 4 (1–7) 55 (11–144) 14 (10–19) NA <.0001
Clinical findings on admission (Y) (Y) (Y) (Y) (Y)  
Fever 203 (57.8) 60 (30.6) 23 (15.5) 21 (38.2) 2 (6.2) <.0001
Local inflammation 282 (80.3) 168 (85.7) 108 (72.9) 47 (85.4) 17 (53.1) <.0001
Shock 27 (7.7) 5 (2.5) 1 (0.6) 3 (5.4) 1 (3.1) .006
Sinus 6 (1.7) 46 (23.4) 71 (47.9) 0 (0.0) 6 (18.7) <.0001
Laboratory findings
Leukocyte count, ×109/L 13.0 (9.7–16.3) 11.3 (8.8–14.1) 9.6 (7.6–11.8) 9.7 (7.4–13.5) 10.8 (7.4–14.8) <.0001
Neutrophil count, ×109/L 10.6 (7.5–14.0) 8.4 (6.6–11.3) 6.6 (5.3–9.3) 7.1 (5.1–9.9) 7.8 (5.0–11.9) <.0001
C-reactive protein, mg/L 230 (135–320) 130 (57–229) 80 (40–169) 132 (56–251) 106 (39–189) <.0001
Creatinine, µmol/L 90 (69–120) 76 (63–94) 79 (65–98) 83 (73–115) 83 (65–95) <.0001
Albumin, g/L 30 (26–36) 30 (25–34) 32 (28–36) 29 (24–33) 31 (27–37) .02
No. of organisms isolated
Culture-negative (0 organisms) 30 (8.5) 18 (9.2) 15 (10.1) 4 (7.3) 7 (21.9)  
Monomicrobial (1 organism) 285 (81.2) 97 (49.5) 104 (70.3) 37 (67.3) 18 (56.2) <.0001
Polymicrobial (≥2 organisms) 36 (10.3) 81 (41.3) 29 (19.6) 14 (25.4) 7 (21.9)  
Microbial etiology1
Staphylococcus aureus 179 (51.0) 79 (40.3) 40 (27.0) 15 (27.2) 9 (28.1) <.0001
MRSA 8 (2.2) 7 (3.5) 8 (5.4) 2 (3.6) 1 (3.1) .52
Coagulase-negative staphylococci 46 (13.1) 59 (30.1) 49 (33.1) 15 (27.2) 9 (28.1) <.0001
β-hemolytic streptococci 58 (16.5) 17 (8.6) 3 (2.0) 8 (14.5) 1 (3.1) <.0001
Enterococci 8 (2.2) 32 (16.3) 8 (5.4) 3 (5.4) 0 (0.0) <.0001
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in LA-PJI (71%) compared with early PJI (38%; P  <  .0001) 
and chronic PJI (49%; P < .0001). Other clinical and labora-
tory characteristics according to classification of PJI type are 
shown (Table 1).
Microbiology
Monomicrobial PJI accounted for 542 (69.2%) infections, 
whereas polymicrobial and culture-negative PJI accounted 
for 167 (21.3%) and 74 (9.5%) infections, respectively. The 
presence of monomicrobial, polymicrobial, and culture-
negative infections according to prosthesis age is shown 
in Figure  2C and D.  After excluding culture-negative in-
fections, polymicrobial infections were less common than 
monomicrobial infections in patients with LA-PJI (11.2%) 
than with either early (46.5%; P  <  .0001) or late (21.8%; 
P  =  .003) PJI. Patients with polymicrobial infections had a 
higher BMI than those with monomicrobial infections (34 vs 
31 kg/m2; P = .002). Across the whole cohort, Staphylococcus 
aureus was the most common pathogen and was present in 
323 (41.2%) patients with PJI.
There were significant differences between the organ-
isms identified in monomicrobial and polymicrobial PJI. 
Enterobacteriaceae, coagulase-negative staphylococci 
(CoNS), enterococcus, and AmpC β-lactamase-producing 
gram-negative organisms were more commonly identified 
in polymicrobial infections (P < .0001). There were also sig-
nificant differences in the micro-organisms isolated between 
PJI classifications and according to the age of the prosthesis 
(Figure 3, Table 1). For patients with early PJI, enterococci 
and gram-negative organisms predominated (P  <  .0001 for 
all comparisons) (Table  1). For chronic infections, CoNS 
were significantly more common (P  <  .0001) (Table  1). 
S.  aureus and β-hemolytic streptococci (BHS) were signifi-
cantly more common in LA-PJI than in early or late chronic 
PJI (P  <  .0001 for both comparisons) (Table  1). One hun-
dred fifty (43%) with LA-PJI had positive blood cultures on 
admission.
Initial Management Strategy at Day 7
The most common initial management strategy was DAIR, 
reported in 520 episodes (66.4%), then 2-stage revision (146, 
18.6%), 1-stage revision (36, 4.6%), antibiotic suppression (53, 
6.7%), excision arthroplasty (7, 0.9%), and “no clear plan” (21, 
2.7%) (Table 2). The median (IQR) time from implantation to 
diagnosis for patients managed with DAIR was 154 (23–1426) 
days, whereas the median duration of symptoms for this group 
of patients was 4 (1–8) days. This surgical approach was under-
taken as the primary management strategy in LA-PJI (247, 
70.3%), early PJI (160, 81.6%), and chronic PJI (66, 44.6%). 
Of patients managed with DAIR, 50 (9.6%) and 37 (7.1%) had 
documented symptoms for ≥21 or ≥30 days, respectively.
Actual Operative Management in the First 90 Days
Excluding those patients for whom there was no clear plan, 
55 patients were managed with a different approach than that 
planned within the first 7 days. This included 17 in the DAIR 
group and 35 in the revision groups (Table 2). Only 7 partici-
pants did not receive any surgical management.
Debridement, Irrigation, Antibiotics, and Implant Retention
Of the 520 patients for whom debridement was the initial 
management strategy, 131 (25.2%) patients had 2 episodes, 32 
(6.2%) had 3 episodes, and 9 (1.7%) had 4 episodes of operative 
debridement. Of the total of 565 DAIR procedures where details 
of the most senior operator was recorded, 157 (27.8%) were per-
formed by a registrar (surgeon in training). Arthroscopic wash-
outs were undertaken on 36 (6.5%) occasions. The reported 
extent of the debridement was only minimal or moderate in 18 
(4.2%) and 124 (29.2%), respectively, with the remainder coded 
as extensive (283, 66.6%). The liner was not exchanged in 104 
(23.4 %) patients (Table 2).
Two-Stage Revision
Details regarding the first stage of a 2-stage revision proce-
dure were available for 178 patients. An articulating spacer 
Characteristic







8–30 d)  
(n = 55)
Late (Unspecified)  
(n = 32) P
ESCAPPM group 4 (1.1) 27 (13.7) 16 (10.8) 7 (12.7) 1 (3.1) <.0001
Initial management strategy (d7)
DAIR 247 (70.4) 160 (81.6) 66 (44.6) 37 (67.3) 10 (31.3)  
Two-stage revision 56 (15.9) 19 (9.7) 51 (34.5) 8 (14.5) 12 (37.5)  
Single-stage revision 9 (2.6) 7 (3.6) 8 (5.4) 3 (5.5) 8 (25.0) <.0001
Antibiotic suppression 27 (7.7) 7 (3.6) 13 (8.8) 5 (9.1) 1 (3.1)  
Excision arthroplasty 2 (0.6) 1 (0.5) 3 (2.0) 0 (0.0) 1 (3.1)  
No clear plan 10 (2.8) 2 (1.0) 7 (4.7) 2 (3.6) 0 (0.0)  
Data are No. (%) for categorical variables and median (interquartile range) for continuous variables. Denominators are those in row 1, unless otherwise stated. 
Abbreviations: DAIR, debridement, antibiotics, irrigation and implant retention; ESCAPPM, organisms with inducible, chomosomally mediated β-lactamase activity including Enterobacter 
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was used in 111 (62.4%) patients, and a nonarticulating 
spacer, other implant, or nothing was inserted into the 
joint space in 57 (32.0%), 8 (4.5%), and 2 (1.1%) patients, 
respectively.
Intra-articular antibiotics were used in 156 (87.6%) pa-
tients. The most common intra-articular antibiotic delivery 
method was through an antibiotic impregnated cement 
spacer in 126 patients. Of 151 patients for whom an intra-
articular antibiotic was recorded, vancomycin was the most 
commonly used (128, 84.8%), followed by gentamicin (47, 
31.1%).
In 41 (27.9%) patients, systemic antibiotics were continued 
until re-implantation. For the remaining 106 patients, anti-
biotics were ceased a median (IQR) of 33 (20–46) days before 
the second stage.
Antibiotic Therapy
Empiric parenteral antibiotics were used in 614 (82.2%) cases. 
Vancomycin was the most commonly prescribed empiric agent 
(279, 45.4%), followed by cefazolin (244, 39.7%), flucloxacillin 
(194, 31.6%), piperacillin-tazobactam (59, 9.6%), and ceftriaxone 
(39, 6.4%). Only 26.9% (165) of patients received adequate 
gram-negative cover in their empiric antibiotic regimen.
The median (IQR) total duration of parenteral antibiotics, 
including empiric and directed therapy prescribed within the 
first 90 days, was 42 (35–48) days (Figure 4). Of 404 patients 
with gram-positive infection who had a DAIR procedure, the 
majority (52.8%) started oral antibiotics during the parenteral 
course. Rifampicin and fusidic acid were used in 209 (56.8%) 
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Figure 2. Duration of time from arthroplasty implantation to diagnosis according to classification of periprosthetic joint infection (A and B), the presence of polymicrobial 
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At least 1 adverse event occurred with parenteral antibiotic 
therapy in 143 (18.2%) patients, resulting in a change of therapy 
in 104 patients. Adverse events were most commonly allergic reac-
tion (32) and acute kidney injury (28). Peripherally inserted central 
catheter (PICC)-associated complications occurred in 14 patients.
DISCUSSION
Key Findings
This large prospective study provides a contemporary descrip-
tion of the clinical characteristics, etiology, and management 
strategies of patients presenting to Australian and New Zealand 
hospitals with a newly diagnosed PJI. Nearly half of classifiable 
cases were LA-PJI, with early postoperative and chronic infec-
tions each accounting for one-quarter or less of the presenta-
tions. There was substantial heterogeneity in the surgical and 
antibiotic management, reflecting the lack of high-quality evi-
dence from randomized trials to guide these decisions.
These data reveal broad patterns in the presentation of PJI 
that could have important implications for empiric antibiotic 
management. Although Staphylococcus aureus is the most 
common pathogen across all groups, early PJIs occur more 
commonly in obese individuals following hip arthroplasty and 
were often caused by polymicrobial infections, with a high 
proportion due to gram-negative organisms and/or entero-
cocci, which are not always covered by empiric antibiotic re-
gimens. By contrast, LA-PJIs present more commonly in knee 
arthroplasties, have higher C-reactive protein concentrations, 
higher proportion of patients reporting fever and a higher pro-
portion of patients with S. aureus and BHS isolated.
Many patients treated with DAIR did not receive debride-
ment that would be considered adequate [13, 14] due to a lack of 
liner exchange, use of arthroscopic debridement, or the failure 
to remove all infected material. Furthermore, 45% of those 
with chronic PJI were treated with DAIR, despite 2-stage revi-
sion being recommended. Outcome data at 24 months are still 
being collated, and it will be important to compare outcomes 
according to adequacy of surgical debridement and concord-




















Figure 3. Duration of time from arthroplasty implantation to diagnosis according to causative organisms isolated. Panels A and B show all organisms cultured. Panels C 
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There was also substantial variation in the approach to 2-stage 
revision. In most patients, there was a substantial delay before 
the second stage, even though this practice has been shown not 
to be necessary [15, 16].
Comparison With the Literature
Such a high proportion of LA-PJI is striking. Few prospective 
studies have reported the proportion of LA-PJI among all pres-
entations with a newly diagnosed PJI. Our data are consistent 
with a prospective study of osteoarticular infections where 
hematogenous spread was thought to be the route of acquisi-
tion for 25 of 58 (43%) infections associated with prosthetic 
material [17] and a large, single-center retrospective study 
demonstrating that 35% were acute hematogenous PJI [11]. By 
contrast, these data are discordant with Spanish data, reporting 
acute haematogenous (AH) PJI in 11.6% of presentations [18], 
and a recent French single-centre study where 10.4% of PJIs 
were classified as AH-PJI [19]. It should be noted that our def-
initions for LA-PJI, which were based on duration from implan-
tation (>30  days) [10, 11] and a short duration of symptoms 
[11, 20] are comparable to those in other studies and are gen-
erally synonymous with the definitions of AH-PJI. To improve 
the specificity of the LA-PJI diagnosis, we also included the 
absence of a sinus to the skin overlying the joint, as this fea-
ture is pathognomonic for chronic late PJI and should usually 
be managed accordingly. The higher proportion of LA-PJI and 
lower proportion of chronic PJI in our data compared with the 
literature in general may be explained by the diverse settings 
of our study that included a range of hospital types and sizes 
and only included a recent, new diagnosis of PJI in the index 
arthroplasty. This contrasts with specialized units with an in-
terest in complex osteoarticular infections, which may be more 
likely to have a highly selected case mix, with an over-represen-
tation of late chronic infections [11] and relapsed PJI, and cor-
respondingly lower proportions of LA-PJI.
A potential explanation is that in a setting where the inci-
dence of arthroplasty is increasing [4], early postoperative PJIs 
might be expected to rise at a proportional rate. But as the cu-
mulative prevalence of people living with a joint replacement 
increases, the population at risk of LA-PJI due to BSI will 
increase at a greater rate.
The observed variability in the management approach of 
PJI is likely to reflect the poor evidence base for current treat-
ment recommendations; the 2012 Infectious Diseases Society of 
Table 2. Surgical Management Approaches of Periprosthetic Infections Used Within the First 90 Days According to Initial Management Strategy at Day 7
Initial Management at 7 d, No. (%) Total 









No Clear Plan 
(n = 21)  
Surgical management at 90 d
 DAIR 486 22 6 8 1 6 529
 2-stage 62 114 1 1 0 1 179
 Single-stage 13 11 32 1 0 2 59
 Suppression 16 4 1 40 0 7 68
 Excision 8 12 1 1 6 3 31
Did not get initial management 17 21 3 13 1 NA 55
No. of surgical management approaches within the first 90 d
0 0 0 0 6 0 1 7
1 422 109 27 43 7 16 624
2 77 24 7 4 0 1 112
3 3 2 0 0 0 0 6
Characteristics of DAIR
 No. of trips to theater
  ≥2 131 5 3 2 0 1 142
  ≥3 32 2 2 2 0 0 38
  4 9 1 1 0 0 0 11
Debridement extent
  Extensive 283 9 2 3 0 3 300
  Moderate 124 10 4 4 1 0 143
  Minimal 18 2 0 0 0 1 21
Most senior operator in theater
  Registrar 157 (27.8) 9 (34.6) 4 (33.3) 3 (30) 0 (0) 2 (40) 175 (28.3)
  Consultant 408 (73.2) 17 (65.4) 8 (66.7) 7 (70) 1 (100) 3 (60) 444 (71.7)
Arthroscopic washout, yes 36 (6.5) 0 (0) 0 (0) 2 (20) 0 (0) 0 (0) 38 (6.3)
Liner exchanged, yes 340 (76.6) 12 (52.2) 4 (66.7) 4 (50) 0 (100) 5 (100) 365 (74.9)
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America guidelines were based on poor (level C) or moderate 
(level B) evidence and evidence types 2 and 3 (observational 
data and expert opinion) [21, 22].
Strengths and Limitations
The PIANO cohort is one of the few truly prospective, 
multicenter, multiregional studies of PJI in the literature. This 
allows an accurate representation of the clinical presentation, 
microbiology, and treatment in typical hospital settings, not 
just specialized units. Because of the inclusion of multiple sites 
from all Australian states and New Zealand, it is likely that these 
findings are generalizable across Australia and New Zealand 
as well as in other similar high-income countries. Despite our 
definitions of PJI being consistent with the literature [11], the 
definition of LA-PJI may have misclassified some patients with 
“chronic” PJI with a short duration of symptoms, and other set-
tings consider PJI occurring up 90 days from implantation to 
be “early” PJI.
CONCLUSIONS
We have confirmed our initial hypotheses that LA-PJI is the 
most common mode of presentation, likely as a result of acute 
hematogenous seeding, and that there is substantial heteroge-
neity in surgical and antibiotic management of PJIs. This has 
important implications for prevention efforts (eg, early identi-
fication and prevention of BSI) and identification of gaps in the 
current evidence (eg, optimal debridement strategy for a DAIR 
procedure, the use of rifampicin in PJI, and the duration of an-
tibiotic therapy). The PIANO cohort will allow analysis of the 
relationship between practice variations and outcome and will 
serve as a platform to build future interventional studies.
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